Human IgG1 kappa, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1 kappa antibody^[1].

Human IgG1 kappa, Isotype Control is often used as the experimental negative control. Human IgG1 kappa, Isotype Control exhibits similar structure and biological properties as human immunoglobulin G1 (IgG1), but lacks specific antigen binding ability^[2].
Human IgG1 kappa, Isotype Control (10 μg/mL, 2-6 h) exhibits no promoting effect on the killing activity of NK cells against CRPC cells or normal prostate epithelial cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Human IgG1 kappa, Isotype Control (10 mg/kg, ip, every 4 days for 4 doses) exhibits no antitumor activity, and has no effects on the mice survival duration in C4-2- or 22RV1 xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

142.68 kDa

Liquid

Colorless to light yellow

[Human IgG1 kappa, Isotype Control]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yunlong Cao, et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020 Jul 9;182(1):73-84.e16.  [Content Brief]

  [2]. Wang F, et al., TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. Cancer Lett. 2023 Aug 1;568:216300.  [Content Brief]